{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:01:30Z","timestamp":1790164890256,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ejso.2026.112059","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T23:33:17Z","timestamp":1786145597000},"page":"112059","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Assessing the value of grade heterogenity among primary tumor and venous tumor thrombus in clear cell renal-cell carcinoma"],"prefix":"10.1016","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5973-789X","authenticated-orcid":false,"given":"Antonio Andrea","family":"Grosso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Mari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Conte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Lambertini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Di Maida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Veccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7352-6327","authenticated-orcid":false,"given":"Anna","family":"Cali\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6630-4881","authenticated-orcid":false,"given":"Maria Rosaria","family":"Raspollini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0126-4731","authenticated-orcid":false,"given":"Francesco","family":"Ditonno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Brunelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1352-4754","authenticated-orcid":false,"given":"Sarah","family":"Malandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Bertolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Antonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Minervini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.ejso.2026.112059_bib1","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMoa2106391","article-title":"Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma","volume":"385","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ejso.2026.112059_bib2","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S1470-2045(22)00487-9","article-title":"Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Powles","year":"2022","journal-title":"Lancet Oncol"},{"issue":"10358","key":"10.1016\/j.ejso.2026.112059_bib3","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/S0140-6736(22)01658-0","article-title":"Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial","volume":"400","author":"Pal","year":"2022","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ejso.2026.112059_bib4","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.eururo.2025.01.014","article-title":"Updated European association of urology guidelines on the use of adjuvant immune checkpoint inhibitors and subsequent therapy for renal cell carcinoma","volume":"87","author":"Bedke","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejso.2026.112059_bib5","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.euros.2022.10.002","article-title":"Is adjuvant immunotherapy worth for all patients with clear-cell renal cell carcinoma at high risk of recurrence?","volume":"46","author":"Marchioni","year":"2022","journal-title":"Eur Urol Open Sci"},{"issue":"1","key":"10.1016\/j.ejso.2026.112059_bib6","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.eururo.2021.02.025","article-title":"Predicting disease recurrence, early progression, and overall survival following surgical resection for high-risk localized and locally advanced renal cell carcinoma","volume":"80","author":"Correa","year":"2021","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ejso.2026.112059_bib7","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0022-5347(05)66077-6","article-title":"A postoperative prognostic nomogram for renal cell carcinoma","volume":"166","author":"Kattan","year":"2001","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.ejso.2026.112059_bib8","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0090-4295(01)01207-9","article-title":"Prognostic assessment of nonmetastatic renal cell carcinoma: a clinically based model","volume":"58","author":"Yaycioglu","year":"2001","journal-title":"Urology"},{"issue":"6","key":"10.1016\/j.ejso.2026.112059_bib9","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1016\/S0022-5347(05)64153-5","article-title":"An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score","volume":"168","author":"Frank","year":"2002","journal-title":"J Urol"},{"issue":"23","key":"10.1016\/j.ejso.2026.112059_bib10","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1200\/JCO.2002.05.111","article-title":"Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma","volume":"20","author":"Zisman","year":"2002","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ejso.2026.112059_bib11","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1111\/j.1464-410X.2003.04505.x","article-title":"A preoperative clinical prognostic model for non-metastatic renal cell carcinoma","volume":"92","author":"Cindolo","year":"2003","journal-title":"BJU Int"},{"issue":"7","key":"10.1016\/j.ejso.2026.112059_bib12","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1002\/cncr.11234","article-title":"Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials","volume":"97","author":"Leibovich","year":"2003","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ejso.2026.112059_bib13","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/01.ju.0000148261.19532.2c","article-title":"A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma","volume":"173","author":"Sorbellini","year":"2005","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.ejso.2026.112059_bib14","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.juro.2006.09.057","article-title":"Dynamic outcome prediction in patients with clear cell renal cell carcinoma treated with radical nephrectomy: the D-SSIGN score","volume":"177","author":"Thompson","year":"2007","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.ejso.2026.112059_bib15","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.eururo.2008.07.037","article-title":"A preoperative prognostic model for patients treated with nephrectomy for renal cell carcinoma","volume":"55","author":"Karakiewicz","year":"2009","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.ejso.2026.112059_bib16","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.juro.2017.04.066","article-title":"Predictive nomogram for recurrence following surgery for nonmetastatic renal cell cancer with tumor thrombus","volume":"198","author":"Abel","year":"2017","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.ejso.2026.112059_bib17","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.eururo.2013.06.048","article-title":"Impact of histologic subtype on cancer-specific survival in patients with renal cell carcinoma and tumor thrombus","volume":"66","author":"Tilki","year":"2014","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.ejso.2026.112059_bib18","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.urolonc.2010.11.017","article-title":"Population based analysis of survival in patients with renal cell carcinoma and venous tumor thrombus","volume":"31","author":"Whitson","year":"2013","journal-title":"Urol Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2026.112059_bib19","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.eururo.2011.05.029","article-title":"Impact of venous tumour thrombus consistency (solid vs friable) on cancer-specific survival in patients with renal cell carcinoma","volume":"60","author":"Bertini","year":"2011","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ejso.2026.112059_bib20","doi-asserted-by":"crossref","first-page":"5760","DOI":"10.1038\/s41467-021-25918-4","article-title":"Determinants of renal cell carcinoma invasion and metastatic competence","volume":"12","author":"Kim","year":"2021","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.ejso.2026.112059_bib22","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.eururo.2022.06.016","article-title":"The 2022 world health Organization classification of tumours of the urinary system and Male genital organs-part A: renal, penile, and testicular tumours","volume":"82","author":"Moch","year":"2022","journal-title":"Eur Urol"},{"issue":"10","key":"10.1016\/j.ejso.2026.112059_bib23","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1097\/PAS.0b013e318299f0fb","article-title":"Members of the ISUP renal tumor panel. The international society of urological pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters","volume":"37","author":"Delahunt","year":"2013","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/j.ejso.2026.112059_bib24","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.euf.2017.01.009","volume":"4","author":"Rodriguez Faba","year":"2018","journal-title":"Eur Urol Focus"},{"issue":"4","key":"10.1016\/j.ejso.2026.112059_bib25","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.eururo.2017.12.018","article-title":"Updates in the eighth edition of the tumor-node-metastasis staging classification for urologic cancers","volume":"73","author":"Paner","year":"2018","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.ejso.2026.112059_bib26","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ajur.2024.09.010","article-title":"Robot-assisted partial nephrectomy for renal cell carcinoma: a narrative review of different clinical scenarios","volume":"12","author":"Grosso","year":"2025","journal-title":"Asian J Urol"},{"issue":"1","key":"10.1016\/j.ejso.2026.112059_bib21","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.euo.2023.06.006","article-title":"Prognostic significance of grade discrepancy between primary tumor and venous thrombus in nonmetastatic clear-cell renal cell carcinoma: analysis of the REMEMBER registry and implications for adjuvant therapy","volume":"7","author":"Wu","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.ejso.2026.112059_bib27","article-title":"mRNA expression, tumor heterogeneity, and response to therapy in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1\u03b1)","volume":"43","author":"Aguzzi","year":"2025","journal-title":"Biochem Biophys Rep"},{"issue":"2","key":"10.1016\/j.ejso.2026.112059_bib28","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.euo.2024.09.002","article-title":"Neoadjuvant and adjuvant immune-based approach for renal cell carcinoma: pros, cons, and future directions","volume":"8","author":"Marandino","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.ejso.2026.112059_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115569","article-title":"Current status of adjuvant immunotherapy and relapse management in renal cell carcinoma: insights from a european Delphi study","volume":"225","author":"Gr\u00fcnwald","year":"2025","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ejso.2026.112059_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2024.102264","article-title":"Cost-Effectiveness analysis of lenvatinib plus pembrolizumab or everolimus as first-line treatment for advanced renal cell carcinoma","volume":"23","author":"Zheng","year":"2025","journal-title":"Clin Genitourin Cancer"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798326006785?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798326006785?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:15:33Z","timestamp":1790162133000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798326006785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0748798326006785"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2026.112059","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessing the value of grade heterogenity among primary tumor and venous tumor thrombus in clear cell renal-cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2026.112059","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"112059"}}